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ABSTRACT Basal cell carcinoma (BCC) is the most frequent skin cancer 
and is characterized by slow growth, even if it can be locally invasive 
and rarely metastasizes. Many different phenotypic presentations and 
histopathologic subtypes have been described, and the current guide-
lines subdivide BCCs into low-risk (nodular and superficial) and high-
risk subtypes (micronodular, infiltrating, and morphoeic BCC and those 
with squamous differentiation). Dermoscopy allows the identification of 
the features associated with these different subtypes. Compared with 
the low-risk forms of BCC, more aggressive ones tend to undergo more 
frequently incomplete surgical excision and perineural invasion, so the 
identification of these lesions before surgery is extremely important. The 
gold standard of treatment is surgery, particularly for the H region of the 
face and infiltrative lesions, but other options are available and selected 
according to many variables, including body area, age, comorbidities, and 
clinical, dermoscopic, and histopathological features of the lesion. More-
over, the possible complications of surgical approaches, namely healing 
defects, failure of skin grafts, and wound infection, should be considered. 
In this review we discuss the management of BCC localized on the face 
and scalp, according to the currently available treatment options.
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INTRODUCTION 
 BCC is the most common skin cancer worldwide 
with increasing incidence, even if it is difficult to as-
sess the real epidemiological data because of the 
current practice of under-registration (1,2). While 
it is still more prevalent in older people, it is also 
becoming frequent in younger individuals (3,4). 
The prognosis is usually good, but despite the low 
mortality rate BCC is a significant cause of morbid-
ity, so early diagnosis and treatment is fundamental 
(5). Exposure to sunlight is the main risk factor, but 
genetic alterations in signaling pathways have a role 
in carcinogenesis as well. New treatment options that 
selectively target these pathways have been recently 
introduced for advanced forms of the disease. The 
choice of the most appropriate treatment is based 
on many factors, including the body area affected, 
the recurrence risk, patient adherence to treatment, 
the extent of the disease, and histopathologic sub-
type (6-8). In this paper, only face and scalp localiza-
tions will be discussed.
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CLINICAL SUBTYPES, DERMATOSCOPY 
AND HISTOPATHOLOGY
 The clinical subtypes of BCC include different 
forms: nodular, ulcerative, superficial, sclerodermi-
form/morpheaform, pigmented, and fibroepithelio-
ma of Pinkus. Many histopathological subtypes have 
also been described: nodular, superficial, infiltrating, 
sclerodermiform/morpheaform, micronodular, fibro-
epithelial, and basosquamous carcinoma (Figure 1). 
The classification system of the National Compre-
hensive Cancer Network (NCCN) based on growth 
pattern identifies two groups: indolent-growth and 
aggressive-growth subtypes (8). The former includes 
nodular and superficial BCC, corresponding to the 
clinical nodular and superficial subtypes, respec-
tively; the latter, which have a higher recurrence 
rate and tend to cause extensive local destruction, 
includes the sclerodermiform/morpheaform, infiltra-
tive, micronodular, and basosquamous subtypes. A 
precise correlation between clinical and histopatho-
logical variants is not always possible; in such cases 
dermoscopy, an non-invasive in vivo technique, may 
be helpful (9,10). Dermoscopy allows early detection 
of BCC and its differentiation from other pigmented 
and non-pigmented lesions (10-18). The spectrum of 
BCC-related criteria has been updated several times 
since the first description, and the most common 
dermoscopic structures currently described include 
globules, dots, white structureless areas, structure-
less gray-brown areas, leaf-like areas, spoke-wheel 
structures, and ulcerations (10) (Figure 2, Figure 3). 
The most frequently found vascular structures in BCC 
are short fine telangiectasia, arborizing vessels, and 
vascular blush (10-18). White shiny structures, which 
include shiny white lines (chrysalis and crystalline 
structures), shiny white areas, and rosettes, only vis-
ible with polarized dermoscopy, represent additional 
criteria to diagnose BCCs (19-20). According to the 
results of recent studies (21-22), some differences in 
dermoscopic appearance between infiltrating and 
other BCC subtypes have been identified. Infiltra-
tive BCC tend to manifest arborizing vessels and ul-
ceration less frequently than nodular BCC, but with 
a greater frequency of shiny white-red structureless 
areas. A study to classify distinct BCC subtypes by re-
flectance confocal microscopy (RCM), a non-invasive 
imaging modality, was carried out as well (23). These 
results are extremely important because the current 
guidelines for the management of BCC suggest im-
plementing a different therapeutic approach accord-
ing to histopathologic subtype, as it is well known 
that infiltrative BCC have higher rates of incomplete 
surgical excision and perineural invasion compared 
with more indolent BCC subtypes. A recent study has 
allowed the identification of a new dermoscopic pat-
tern in infiltrative BCC, described by the authors as a 
“stellate pattern” (8,24,25). This pattern consists of a 
geometric star extending outwards from the circum-
ferential peripheral edge of the tumor and identified 
by white lines, vessels, or uneven skin surface mor-
phology. This evidence highlights how dermoscopy 
can be useful in providing information on the tumor 
subtype in the preoperative assessment (26-29).
TREATMENT
 The choice of BCC treatment should take into ac-
count several factors such as anatomic site, histologic 
features, tumor recurrence, and the patient’s general 
Figure 1. Clinical aspect of basal cell cancer of the ear.
Figure 2. Dermoscopic image of nodular basal cell carci-
noma with short fine telangiectasia.
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characteristics. The NCCN stratifies BCCs into low- and 
high-risk subtypes based on location, size, borders, 
recurrence, immunosuppression, site of prior radia-
tion treatment, pathological subtype, and evidence 
of perineural involvement (8). Treatment modalities 
include surgical excision, electrodessication and cu-
rettage, cryotherapy, topical immunotherapy, pho-
todynamic therapy, and radiation therapy. Moreover, 
locally advanced or metastatic BCC are currently 
treated with the new targeted molecular drugs (30).
Surgical or destructive modalities 
Standard excision
 Standard excision represents the gold standard 
treatment for the histological forms of primary non-
aggressive BCCs (nodular or superficial) or for those 
occurring on low-risk sites (trunk/extremities). Clas-
sifying primary or recurrent tumors is essential for 
surgical planning, because primary BCCs have lower 
recurrence rates than previously treated BCCs and the 
margins necessary for complete eradication of recur-
rent tumors are almost twice as big as those required 
to eradicate primary BCCs. A 4 mm excision margin is 
indicated in lesions smaller than 2 cm in diameter.
Mohs’ micrographic surgery
 Mohs’ micrographic surgery (MMS) allows optimal 
margin control with the preservation of normal tis-
sue. It is the treatment of choice for all high-risk le-
sions, recurrent BCCs, as well as primary BCCs located 
on anatomic sites requiring functional and aesthetic 
maintenance such as those localized on the eyes, lips, 
or nose (30,31).
Electrodessication and curettage
 For appropriately selected lesions, electrodessica-
tion and curettage remains an efficacious and cost-
effective treatment modality for BCC, but it is now 
less frequently used due to new treatment modalities 
and the lack of histopathological examination of the 
lesion (32).
Cryosurgery
 BCC can also be treated with cryosurgery (liquid 
nitrogen at −196 °C) according to the principle that 
freezing cycles with subzero temperatures destroy 
the tumor tissue with subsequent healing. A margin 
of clinically normal tissue must be included to also 
eradicate subclinical extension. Cryosurgery is only 
occasionally used for superficial or small-sized BCCs 
(31).
Non-surgical options
 These include topical, systemic, and radiation 
therapy (33).
Imiquimod
 Imiquimod 5% cream has been approved by the 
US Food and Drug Administration (FDA) for the six 
week treatment duration of primary superficial BCCs 
smaller than 2 cm, in low-risk anatomic locations. 
Moreover, a recent study demonstrated that it can 
be a valuable adjuvant therapy for the treatment of 
incompletely excised nodular BCC in elderly people 
(34-36).
Photodynamic therapy
 According to the results of a recent meta-analy-
sis, photodynamic therapy (PDT) represents a useful 
method for the treatment of BCC, with similar efficacy 
to cryosurgery and pharmacologic treatments and 
lower only compared with surgical excision (37). PTD 
involves the activation of a photosensitizing drug: 
5-aminolevulinic acid (5-ALA) or methylaminolevu-
linate (MAL) by a source of light to produce reactive 
oxygen species (ROS) that destroy cancer cells. It is 
indicated for patients with multiple non-aggressive 
BCCs (i.e. Gorlin-Goltz patients) or for those that are 
not candidates for surgery. Recently, MAL-PDT has 
been described as an effective treatment in the man-
agement of thin nodular BCC (thickness <2 mm) (38). 
MAL-PDT has been reported to also be effective in 
reducing tumor size in sclerodermiform BCC before 
surgery and may also be considered for pigmented 
Figure 3. Dermoscopic image of superficial basal cell carci-
noma characterized by a structureless gray-brown area and 
arborizing vessels.
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BCCs after an adequate debulking; however, patients 
should be closely followed due to the higher recur-
rence risk (38-40). Finally, MAL-PDT has shown good 
results in treating giant BCC, particularly in associa-
tion with topical imiquimod, allowing a considerable 
reduction in the tumoral dimension with subsequent 
more conservative excision (38,41).
Targeted molecular therapy
 Until 2012, when Vismodegib, a Smoothened 
(SMO) inhibitor acting on the Hedgehog molecular 
pathway, was approved, the therapeutic approach 
for patients with locally advanced or metastatic BCC 
was exclusively represented by conventional chemo-
therapy. Vismodegib received approval by the FDA in 
January 2012 and by the European Medicines Agency 
(EMA) in July 2013 after a phase II study on 96 ad-
vanced BCCs, where it demonstrated a response rate 
of 30% in patients with metastatic BCC and 43% in 
locally advanced tumors (42). New SMO antagonists 
and itraconazole are currently under investigation in 
phase I-III clinical trials (43,44).
Radiation therapy
 Radiotherapy represents a treatment option for 
those patients who cannot undergo surgery or who 
refuse surgical approach. It is also used as adjuvant 
therapy for BCC where postoperative margins are 
positive or in case of perineural involvement (32).
Future Perspectives in BCC Treatment
 Daylight photodynamic therapy (DL-PDT) is a 
promising treatment. It has been used in a preliminary 
study of 21 patients with 32 BCCs, where it achieved 
90% 3-month complete clinical response rate, even if 
6 patients presented with a recurrence during the 12-
month follow-up (44). Recent studies investigated the 
use of ingenol mebutate for patients with BCC who 
failed or were ineligible for conventional treatments 
(45,46). The complete clinical response rates were 
82% and 57% after 1 and 15 months, respectively. In 
another phase II trial (46), the histologically confirmed 
clearance of the treated lesions was reported in 65% 
of the study population, with higher efficacy in those 
patients treated for 2 consecutive days.
FOLLOW-UP, RISK OF RECURRENCE AND 
PREDICTORS FOR A SECOND BCC
 The NCCN recommendations for follow-up of pa-
tients with BCC include 6- to 12-month total body 
skin examination by a dermatologist, sun protection 
measures, and skin self-examinations (8). Up to 50% 
of patients with primary BCC is estimated to develop 
at least one other BCC within 5 years. Verkouteren 
et al. have recently carried out a study in which they 
concluded that a combination of clinical character-
istics (phenotypic traits, lifestyle, and tumor-specific 
characteristics) could identify patients at high risk for 
a second BCC (47). The recurrence rate is higher in in-
completely excised lesions, and primary BCC recurs 
less often than previously treated BCC. It is not well 
known whether gender can influence the recurrence 
rate of BCC, but data from the literature report that 
BCC recurs more often in men (48-50). Incomplete 
excision has been reported to be more common in 
women, however, probably due to major aesthetic 
needs (51).
CONCLUSION
 BCC is the most common skin cancer worldwide 
with increasing incidence, affecting mainly photo-ex-
posed areas, even if genetic alterations play a pivotal 
role in its carcinogenesis. Different histopathologic 
subtypes have been described, presenting different 
behaviors. In particular, the superficial type has the 
most indolent prognosis. Dermoscopy aids in iden-
tifying the features associated with these different 
subtypes and is extremely important for manage-
ment since the current guidelines suggest different 
therapeutic approaches according to histopathologic 
subtype. Although surgical excision is the gold stan-
dard of treatment, preservation of functions, cosmet-
ic concerns, and patient age, as well as tumor prog-
nostic factors, should guide the treatment choice. 
Therefore, a multidisciplinary approach is strongly 
recommended for the optimal management of BCC.
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